WAVE LIFE SCIENCES LTD (WVE) Fundamental Analysis & Valuation

NASDAQ:WVE • SG9999014716

13.12 USD
-0.08 (-0.61%)
At close: Mar 6, 2026
13.35 USD
+0.23 (+1.75%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This WVE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to WVE. WVE was compared to 193 industry peers in the Pharmaceuticals industry. While WVE has a great health rating, there are worries on its profitability. WVE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. WVE Profitability Analysis

1.1 Basic Checks

  • In the past year WVE has reported negative net income.
  • In the past year WVE has reported a negative cash flow from operations.
  • In the past 5 years WVE always reported negative net income.
  • WVE had a negative operating cash flow in each of the past 5 years.
WVE Yearly Net Income VS EBIT VS OCF VS FCFWVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • The Return On Assets of WVE (-32.01%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -38.84%, WVE is in line with its industry, outperforming 58.03% of the companies in the same industry.
Industry RankSector Rank
ROA -32.01%
ROE -38.84%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-50.01%
ROE(3y)-68.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WVE Yearly ROA, ROE, ROICWVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for WVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WVE Yearly Profit, Operating, Gross MarginsWVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. WVE Health Analysis

2.1 Basic Checks

  • WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for WVE has been increased compared to 1 year ago.
  • Compared to 5 years ago, WVE has more shares outstanding
  • There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
WVE Yearly Shares OutstandingWVE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
WVE Yearly Total Debt VS Total AssetsWVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 10.30 indicates that WVE is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 10.30, WVE belongs to the best of the industry, outperforming 83.94% of the companies in the same industry.
  • There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.3
ROIC/WACCN/A
WACC9.34%
WVE Yearly LT Debt VS Equity VS FCFWVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 6.47 indicates that WVE has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.47, WVE is in the better half of the industry, outperforming 70.47% of the companies in the same industry.
  • A Quick Ratio of 6.47 indicates that WVE has no problem at all paying its short term obligations.
  • WVE's Quick ratio of 6.47 is fine compared to the rest of the industry. WVE outperforms 71.50% of its industry peers.
Industry RankSector Rank
Current Ratio 6.47
Quick Ratio 6.47
WVE Yearly Current Assets VS Current LiabilitesWVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. WVE Growth Analysis

3.1 Past

  • The earnings per share for WVE have decreased strongly by -54.43% in the last year.
  • Looking at the last year, WVE shows a very negative growth in Revenue. The Revenue has decreased by -60.55% in the last year.
  • The Revenue has been growing by 16.30% on average over the past years. This is quite good.
EPS 1Y (TTM)-54.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-276.47%
Revenue 1Y (TTM)-60.55%
Revenue growth 3Y127.06%
Revenue growth 5Y16.3%
Sales Q2Q%-79.41%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.26% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, WVE will show a very strong growth in Revenue. The Revenue will grow by 71.03% on average per year.
EPS Next Y-11.38%
EPS Next 2Y-3.25%
EPS Next 3Y1.95%
EPS Next 5Y25.26%
Revenue Next Year-8.37%
Revenue Next 2Y41.96%
Revenue Next 3Y63.77%
Revenue Next 5Y71.03%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
WVE Yearly Revenue VS EstimatesWVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
WVE Yearly EPS VS EstimatesWVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. WVE Valuation Analysis

4.1 Price/Earnings Ratio

  • WVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for WVE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WVE Price Earnings VS Forward Price EarningsWVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WVE Per share dataWVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.25%
EPS Next 3Y1.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. WVE Dividend Analysis

5.1 Amount

  • WVE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

WVE Fundamentals: All Metrics, Ratios and Statistics

WAVE LIFE SCIENCES LTD

NASDAQ:WVE (3/6/2026, 8:00:02 PM)

After market: 13.35 +0.23 (+1.75%)

13.12

-0.08 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners97.99%
Inst Owner Change24.97%
Ins Owners0.49%
Ins Owner Change2.65%
Market Cap2.47B
Revenue(TTM)42.73M
Net Income(TTM)-204.38M
Analysts85
Price Target34.17 (160.44%)
Short Float %9.45%
Short Ratio4.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.09%
Min EPS beat(2)-9.98%
Max EPS beat(2)-6.2%
EPS beat(4)0
Avg EPS beat(4)-7.97%
Min EPS beat(4)-10.05%
Max EPS beat(4)-5.63%
EPS beat(8)1
Avg EPS beat(8)8.2%
EPS beat(12)4
Avg EPS beat(12)-24.1%
EPS beat(16)5
Avg EPS beat(16)-19.36%
Revenue beat(2)1
Avg Revenue beat(2)-13.78%
Min Revenue beat(2)-32.32%
Max Revenue beat(2)4.76%
Revenue beat(4)1
Avg Revenue beat(4)-17.69%
Min Revenue beat(4)-32.32%
Max Revenue beat(4)4.76%
Revenue beat(8)2
Avg Revenue beat(8)-10.7%
Revenue beat(12)5
Avg Revenue beat(12)15.21%
Revenue beat(16)5
Avg Revenue beat(16)-8.86%
PT rev (1m)0%
PT rev (3m)68.03%
EPS NQ rev (1m)-0.25%
EPS NQ rev (3m)0.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.23%
Revenue NQ rev (1m)-3.64%
Revenue NQ rev (3m)8.1%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)-9.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 57.81
P/FCF N/A
P/OCF N/A
P/B 4.69
P/tB 4.69
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.23
BVpS2.8
TBVpS2.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.01%
ROE -38.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-50.01%
ROE(3y)-68.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.87%
Cap/Sales 1.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.47
Quick Ratio 6.47
Altman-Z 10.3
F-Score3
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)22.42%
Cap/Depr(5y)19.09%
Cap/Sales(3y)1.18%
Cap/Sales(5y)8.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-276.47%
EPS Next Y-11.38%
EPS Next 2Y-3.25%
EPS Next 3Y1.95%
EPS Next 5Y25.26%
Revenue 1Y (TTM)-60.55%
Revenue growth 3Y127.06%
Revenue growth 5Y16.3%
Sales Q2Q%-79.41%
Revenue Next Year-8.37%
Revenue Next 2Y41.96%
Revenue Next 3Y63.77%
Revenue Next 5Y71.03%
EBIT growth 1Y-94.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.15%
OCF growth 3YN/A
OCF growth 5YN/A

WAVE LIFE SCIENCES LTD / WVE FAQ

What is the ChartMill fundamental rating of WAVE LIFE SCIENCES LTD (WVE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to WVE.


What is the valuation status for WVE stock?

ChartMill assigns a valuation rating of 0 / 10 to WAVE LIFE SCIENCES LTD (WVE). This can be considered as Overvalued.


How profitable is WAVE LIFE SCIENCES LTD (WVE) stock?

WAVE LIFE SCIENCES LTD (WVE) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for WVE stock?

The Earnings per Share (EPS) of WAVE LIFE SCIENCES LTD (WVE) is expected to decline by -11.38% in the next year.